Sutro Biopharma (STRO) Fundamental Analysis: Revenue, Earnings & Valuation

1.41 / 10

Underperform

Fundamental metrics rate STRO as underperform with a 1.4/10 score. Turnover ratios (inventory, receivables, fixed assets) are modestly positive, but income‑tax‑to‑profit, PB‑ROE and asset‑to‑market values are negative, dragging overall quality down.

Analysis Checks(7/10)

Revenue-MV

Value-0.47

Score2/3

Weight45.15%

1M Return6.87%

Total operating revenue (YoY growth rate %)

Value92.31

Score2/3

Weight2.83%

1M Return0.58%

Inventory turnover ratio

Value47.57

Score3/3

Weight-3.02%

1M Return-0.67%

Accounts receivable turnover ratio

Value14.49

Score2/3

Weight-2.99%

1M Return-0.65%

PB-ROE

Value-0.71

Score1/3

Weight28.24%

1M Return5.22%

Income tax / Total profit (%)

Value0.01

Score0/3

Weight-6.81%

1M Return-1.54%

Fixed assets turnover ratio

Value2.90

Score2/3

Weight-4.78%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-3.38%

1M Return-0.73%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-3.32%

1M Return-0.74%

Asset-MV

Value-0.48

Score1/3

Weight48.07%

1M Return7.28%

Is STRO fundamentally strong?

STRO scores 1.41/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -186.45% net margin, -2.04 P/E ratio, -2.94 P/B ratio, and 23.50% earnings growth, these metrics solidify its Underperform investment rating.